{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:53:07Z","timestamp":1776279187531,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":7251,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,3]]},"DOI":"10.1023\/a:1008398725442","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T09:41:38Z","timestamp":1040550098000},"page":"333-338","source":"Crossref","is-referenced-by-count":18,"title":["A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors"],"prefix":"10.1016","volume":"11","author":[{"given":"A.W.","family":"Tolcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Aylesworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Izbicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.K.","family":"Rowinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008398725442_bb0100","first-page":"1941","article-title":"Dolastatin 10, a powerful cytostatic peptide derived from a marine animal","volume":"39","author":"Bai","year":"1990","journal-title":"Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol"},{"key":"10.1023\/A:1008398725442_bb0105","first-page":"66","article-title":"Studies on macrocyclic lactone antibiotic","volume":"40","author":"Takahashi","year":"1987","journal-title":"Xi. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues [published erratum appeared in J Antibiot (Tokyo) 1987; 40 (4): following 565]. J Antibiot"},{"key":"10.1023\/A:1008398725442_bb0110","series-title":"Cancer Res","article-title":"Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines","author":"Tsuruo","year":"1986"},{"key":"10.1023\/A:1008398725442_bb0115","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/oxfordjournals.annonc.a058334","article-title":"Preclinical anti-tumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent [see comments]","volume":"3","author":"Hendriks","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008398725442_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF01240315","article-title":"In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance","volume":"123","author":"Anoka","year":"1997","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1023\/A:1008398725442_bb0125","first-page":"2894","article-title":"Phase I and pharmacokinetic atudy of rhizoxin","volume":"52","author":"Bissett","year":"1992","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008398725442_bb0130","first-page":"1944","article-title":"Multicentre phase II pharmacological evaluation of rhizoxin","volume":"74","author":"McLeod","year":"1996","journal-title":"Eortc early clinical studies (ECSG)\/pharmacology and molecular mechanisms (PAMM) groups. Br J Cancer"},{"key":"10.1023\/A:1008398725442_bb0135","series-title":"Br J Cancer","article-title":"Single-agent activity of rhizoxin in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group","author":"Kaplan","year":"1996"},{"key":"10.1023\/A:1008398725442_bb0140","first-page":"400","article-title":"Phase II study of rhizoxin in squamous-cell head and neck cancer","volume":"73","author":"Verweij","year":"1996","journal-title":"The EORTC Early Clinical Trials Group. Br J Cancer"},{"key":"10.1023\/A:1008398725442_bb0145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1126\/science.560061","article-title":"Primary bioassay of human tumor stem cells","volume":"197","author":"Hamburger","year":"1977","journal-title":"Science"},{"key":"10.1023\/A:1008398725442_bb0150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/jnci\/82.2.110","article-title":"Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician [see comments],","volume":"82","author":"Von Hoff","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008398725442_bb0155","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1248\/cpb.33.1164","article-title":"New labeling reagents for alcohols in fluorescence high-performance liquid chromatography","volume":"33","author":"Takadate","year":"1985","journal-title":"Chem Pharmacol Bull"},{"key":"10.1023\/A:1008398725442_bb0160","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1200\/JCO.1994.12.10.2102","article-title":"Phase I\u2013II trial of continuous infusion vinorelbine for advanced breast cancer","volume":"12","author":"Toussaint","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008398725442_bb0165","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1200\/JCO.1994.12.8.1621","article-title":"Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I\u2013II trial of 96-hour infusion","volume":"12","author":"Wilson","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008398725442_bb0170","series-title":"Proc Annu Meet Am Soc Clin Oncol","article-title":"Phase III trial of paclitaxel (P) administered over 3- or 96-hour for metastatic breast cancer (MBC) (Meeting abstract)","author":"Holmes","year":"1996"},{"key":"10.1023\/A:1008398725442_bb0175","series-title":"Proc Annu Meet Am Soc Clin Oncol","article-title":"Phase I clinical and pharmacokinetic study of rhizoxin (R) administered as a 72-hour (hr) continuous infusion (CIV) (Meeting abstract)","author":"Fleming","year":"1997"},{"key":"10.1023\/A:1008398725442_bb0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO.1998.16.1.153","article-title":"Phase I trial of weekly paclitaxel in advanced lung cancer","volume":"16","author":"Akerley","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008398725442_bb0185","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.1998.16.6.2164","article-title":"Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer","volume":"16","author":"Hainsworth","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008398725442_bb0190","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1997.15.1.187","article-title":"Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer","volume":"15","author":"Fennelly","year":"1997","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420315283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420315283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/3\/333\/19478370\/11-3-333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:38:58Z","timestamp":1582166338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420315283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["S0923753420315283"],"URL":"https:\/\/doi.org\/10.1023\/a:1008398725442","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}